Titan Medical Inc

Titan Medical, Inc. engages in the research and development of a computer-assisted robotic surgical technology for application in minimally invasive surgery (MIS). Its portfolio, the Enos™ system, is a robotic single access surgery with dual 3D and 2D definition vision systems, multi-articulating instruments, and a surgeon workstation. The company was founded on July 28, 2008 and is headquartered in Toronto, Canada.

Quantum International Corp. operates as an emerging robotics innovation company. It identifies and develops innovative products in the robotics, consumer electronics and lifestyle enhancement products. The company was founded on September 25, 2001 and is headquartered in Centennial, CO.

TORONTO, Ontario, May 15, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Order s (“NP 12-203”).

Titan Medical Provides Bi-Weekly MCTO Status Update

TORONTO, ON, April 04, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) announces that it has been granted a management cease trade order (“MCTO”) by the Ontario Securities Commission (the “OSC”), as its principal regulator, under National Policy 12-203 – Cease Trade Orders for Continuous Disclosure Defaults (“NP 12-203”).

Titan Medical Announces Receipt of MCTO

TORONTO, ON, April 03, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) today provided an update on its annual filings and certain other corporate and operational matters.

Titan Medical Provides Corporate Update

TORONTO, ON, March 22, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) today announces that, as a result of certain financial and operational challenges that the Company has experienced over the past several months and as a result of the Company devoting significant management resources to rectifying these challenges, the Company will not be filing its annual financial statements, the related management's discussion and analysis and annual information form, and the accompanying chief executive officer and chief financial officer certification for its financial year ended December 31, 2022 (the “Annual Filings”), within 90 days of December 31, 2022, as required under Parts 4 and 5 of National Instrument 51-102 – Continuous Disclosure Obligations and National Instrument 52-109 – Certification of Disclosure in Issuers' Annual and Interim Filings.

Titan Medical Announces Delays in its Annual Filings and Planned Deregistration with the SEC

Common shares to continue to trade on the Toronto Stock Exchange and are expected to trade on the OTC Markets Common shares to continue to trade on the Toronto Stock Exchange and are expected to trade on the OTC Markets

Titan Medical Announces Decision of Nasdaq Hearings Panel to Delist Common Shares

AMC Preferred Equity Unit

Sera Prognostics

Debunking common myths about trading penny stocks in 2023 The post 3 Common Myths About Penny Stocks Debunked  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Common Myths About Penny Stocks Debunked

Toronto, Ontario, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (the “Company” or “Titan”) (Nasdaq: TMDI; TSX: TMD) today announced senior leadership changes and the receipt of a notification from the Nasdaq Stock Market LLC Listing Qualifications Department stating that following the resignation of Heather Knight from the Company's board of directors and audit committee, the Company no longer complies with Nasdaq's audit committee requirement set forth in Nasdaq Rule 5605.

Titan Medical Announces Executive Leadership Updates and Receipt of Nasdaq Notification Regarding Audit Committee Requirements

TORONTO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced the unveiling of its next generation technology and participation in meetings to support the strategic review process announced on November 30, 2022 alongside the 41st Annual J.P. Morgan Healthcare Conference being held January 9-12 in San Francisco, CA. A video highlighting the company's latest innovation in robotic-assisted surgery is available on the company's website www.titanmedicalinc.com.

Titan Medical Shares Latest Technology Innovation and Announces Meeting Participation During J.P. Morgan Healthcare Conference Week

TORONTO, ON, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) (the “Company”), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that, on December 27, 2022, the Nasdaq Listing Qualifications Staff (the “Staff”) notified the Company that, based upon the Company's non-compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Rule”) as of December 26, 2022, the Company's securities would be delisted unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing, which request will stay any further action by the Staff at least pending the issuance of the Panel's decision following the hearing and the expiration of any extension that may be granted by the Panel.

Titan Medical Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing

TORONTO, ON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that the United States Patent and Trademark Office (USPTO) recently issued patent No. 11,504,191, titled “Graphical User Interface for a Robotic Surgical System.” The patent, directed at enhancing the surgeon user experience, generally covers a graphical user interface (GUI) overlay of a surgical workspace to track instrument movement.

Titan Medical Granted Patent Covering User Experience, Further Enhancing its Intellectual Property in Robotic Assisted Surgery

Akebia Therapeutics

The Beachbody Co.

ComSovereign Holding

Faraday Future Intelligent Electric

Nymox Pharmaceutical

Rigel Pharmaceuticals

Sonim Technologies Inc

Statera Biopharma Inc

Tricida Inc

Penny stocks under $1 to watch this week. The post 10 Top Penny Stocks To Watch Under $1 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Watch Under $1 This Week

TORONTO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that in view of the commencement of the strategic review process announced on November 30, 2022, the special meeting of its shareholders scheduled for January 12, 2023 will be suspended and, if appropriate and necessary, rescheduled to a future date. If rescheduled to a future date, the business of the meeting may include, to the extent required by corporate or securities law and as determined by the Board of Directors of the company, the approval of a potential transaction should one result from the strategic review process announced on November 30, 2022 or, if appropriate, the approval of a consolidation of the company's common shares. No future meeting dates have been scheduled and no decision on any specific business item for any future meeting of shareholders has been made at this time.

Titan Medical Suspends Special Meeting of Shareholders in Conjunction with Initiation of Strategic Review Process

TORONTO, ON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will implement certain cost-cutting measures with a view to preserving capital to support the strategic review process announced on November 30, 2022 while allowing the company to continue working on the investigational device exemption (IDE) filing with the U.S. Food and Drug Administration (FDA). As part of this plan, the company's U.S. subsidiary will be temporarily furloughing approximately 40 employees at its Chapel Hill, North Carolina facility effective immediately.

Titan Medical Implements Cost-Cutting Measures to Support Strategic Review Process

TORONTO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) (“Titan” or the “Company”), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that its Board of Directors (or the “Board”), in consultation with its financial and legal advisors, has determined that it is in the best interest of the Company and its stakeholders to undertake a review and evaluation of strategic alternatives that may be available to the Company to unlock shareholder value. As part of the process, the Board will consider a full range of strategic alternatives including corporate sale, merger or other business combination, a sale of all or a portion of the company's assets, strategic investment or other significant transaction.

Titan Medical Announces Commencement of Strategic Review Process

TORONTO, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced its attendance at the American Association of Gynecologic Laparoscopy (AAGL) 51st Global Congress on minimally invasive gynecologic surgery (MIGS) being held December 1-4, 2022 in Aurora, Colorado.

Titan Medical Announces American Association of Gynecologic Laparoscopy Global Congress Participation

Titan Medical Inc. (NASDAQ:TMDI ) Q3 2022 Earnings Conference Call November 10, 2022 8:30 AM ET Company Participants Kristen Galfetti - VP of IR Cary Vance - President & CEO Stephen Lemieux - CFO Conference Call Participants Operator Good morning, and welcome to Titan Medical's Third Quarter 2022 Earnings Conference Call. After the presentation, there will be an opportunity for call participants to ask questions.

Titan Medical Inc. (TMDI) Q3 2022 Earnings Call Transcript

Shareholder Meeting to Support Share Consolidation to Maintain Nasdaq Listing Shareholder Meeting to Support Share Consolidation to Maintain Nasdaq Listing

Titan Medical Reports Financial Results for the Third Quarter 2022, and Announces Special Shareholder Meeting

Webcast to Follow Announcement Webcast to Follow Announcement

Titan Medical to Issue Third Quarter 2022 Financial Results on November 10, 2022

TORONTO, ON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that Eric Heinz has been appointed as the company's Vice President, Market and Corporate Development. Mr. Heinz will be responsible for developing and executing on strategic business plans to expand and accelerate Titan's Enos™ robotic single access surgical system's portfolio cadence. He will also lead existing partnerships and look to supplement those to maximize Titan's reach and the utilization of the Enos system. Mr. Heinz will engage and collaborate with stakeholders in refining the company's value proposition, branding, product positioning and core messaging.

Titan Medical Announces Appointment of Eric Heinz as Vice President, Market and Corporate Development

Strengthens company's intellectual property portfolio with innovations in next generation single access RAS technology Strengthens company's intellectual property portfolio with innovations in next generation single access RAS technology

Titan Medical Announces Publication of Patent Application Expanding Commitment to Continued Innovation in Single Access Robotic Assisted Surgery

Titan to support Medtronic development and pre-clinical activities through supply of instruments and cameras Titan to support Medtronic development and pre-clinical activities through supply of instruments and cameras

Titan Medical Signs Definitive Agreement with Medtronic

TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will present an overview of its Enos™ robotic single access surgical system at the H.C. Wainwright Global Investment Hybrid Conference, taking place September 12-14, 2022 at the Lotte New York Palace Hotel in New York, NY, and virtually.

Titan Medical to Present at the H.C. Wainwright Global Investment Conference

Titan Medical Inc. (NASDAQ:TMDI ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Kristen Galfetti - Vice President of Investor Relations Cary Vance - President & Chief Executive Officer Stephen Lemieux - Chief Financial Officer Conference Call Participants Suraj Kalia - Oppenheimer & Co. Operator Hello, and welcome to the Titan Medical Inc. Q2 2022 Financial and Business Update, Webcast and Live Call. All participants will be in listen only mode.

Titan Medical Inc. (TMDI) CEO Cary Vance on Q2 2022 Results - Earnings Call Transcript

New CEO Appointed, Manufacturing Progress Noted New CEO Appointed, Manufacturing Progress Noted

News for Titan Medical Inc Stock (TMDI)